GC Green Cross Wellbeing Successfully Holds Ceremony to Mark 100 Millionth Laennec Ampoule Shipment

"Toward Greater Growth as a Global Bio Company"

GC Green Cross Wellbeing announced on the 14th that it successfully held a ceremony the previous day at the Eumseong Innovation Factory in Chungbuk to commemorate the shipment of 100 million ampoules of its specialty pharmaceutical product, the human placenta injection "Laennec" — the first time for such a milestone ever to be achieved domestically.

Jo Byungok, Eumseong County Governor (left), and Kim Sanghyun, CEO of GC Green Cross Wellbeing, are taking a commemorative photo at the event celebrating the shipment of 100 million ampoules of Lineczu at the Eumseong Innovation Factory in Chungbuk on the 13th. GC Green Cross Wellbeing

Since its launch in 2005, Laennec has dominated the domestic placenta injection market with an overwhelming market share of 80%, solidifying its leading position. GC Green Cross Wellbeing stated, "Achieving 100 million ampoules in total shipments is the result of over 20 years of our product's quality and safety being recognized by medical professionals and patients. It is a symbolic achievement that demonstrates GC Green Cross Wellbeing's unrivaled competitiveness in pioneering the domestic human placenta pharmaceutical market."

In his welcoming address, Kim Sanghyun, CEO of GC Green Cross Wellbeing, said, "It is significant that Laennec, the only human placenta hydrolysate product in Korea, has surpassed a cumulative shipment of 100 million ampoules." He added, "Moving forward, we plan to continue our growth as a global bio company by utilizing not only human placenta, but also various other human-derived materials such as adipose tissue, extracellular matrix (ECM), and collagen, in line with future changes in relevant laws and regulations."

This content was produced with the assistance of AI translation services.